(Q43745881)

26 November 2017

title

Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro (English)

1 reference

26 November 2017

P J Guillou

1 reference

26 November 2017

P C Sedman

series ordinal

1 reference

26 November 2017

C W Ramsden

series ordinal

1 reference

26 November 2017

publication date

1 January 1989

1 reference

Cancer Immunology, Immunotherapy

26 November 2017

published in

1 reference

26 November 2017

1 reference

26 November 2017

1 reference

26 November 2017

page(s)

43-53

1 reference

Immunoregulatory properties of human esophageal tumor extract

26 November 2017

cites work

1 reference

12 December 2020

Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model

1 reference

12 December 2020

Interferon gamma regulates HLA-D expression on solid tumors in vivo

1 reference

12 December 2020

Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells

1 reference

12 December 2020

Lymphokine-activated killer cells. Analysis of progenitors and effectors

1 reference

12 December 2020

Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.

1 reference

12 December 2020

Role of natural killer cells in the destruction of circulating tumor emboli

1 reference

12 December 2020

The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells

1 reference

12 December 2020

Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response

1 reference

12 December 2020

Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes

1 reference

12 December 2020

Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria

1 reference

12 December 2020

A possible role of prostaglandins in the inhibition of natural and antibody-dependent cell-mediated cytotoxicity against tumor cells

1 reference

12 December 2020

Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro

1 reference

12 December 2020

The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Natural killer-cell activity, interferon-alpha 2 production, and interleukin-2 production in cyclosporine-treated and conventionally immunosuppressed human allograft recipients

1 reference

12 December 2020

Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes

1 reference

12 December 2020

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness

1 reference

12 December 2020

Immunoregulatory factors derived from human tumors. II. Partial purification and further immunobiochemical characterization of a human sarcoma-derived immunosuppressive factor expressing HLA-DR and immunoglobulin-related determinants

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2

1 reference

12 December 2020

Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver.

1 reference

12 December 2020

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types

1 reference

12 December 2020

Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer

1 reference

12 December 2020

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

12 December 2020

An inhibitor of lymphocyte proliferation produced by a human colonic adenocarcinoma cell line in culture

1 reference

12 December 2020

Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro

1 reference

12 December 2020

Mechanism of cell contact-mediated inhibition of natural killer activity

1 reference

12 December 2020

Systemic administration of interleukin-2 in humans

1 reference

12 December 2020

Generation of activated killer cells in tumor-bearing hosts

1 reference

12 December 2020

Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells

1 reference

12 December 2020

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Inhibition of normal allogenic lymphocyte mitogenesis by a soluble inhibitor extracted from human colonic carcinoma.

1 reference

12 December 2020

Autocrine secretion and malignant transformation of cells.

1 reference

12 December 2020

Decreased interleukin-2 production in patients with gastrointestinal cancer

1 reference

12 December 2020

Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy

1 reference

12 December 2020

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells

1 reference

12 December 2020

Augmentation of lymphokine-activated killer cell activity in patients with gastrointestinal cancer

1 reference

12 December 2020

Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).

1 reference

12 December 2020

A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function

1 reference

12 December 2020

Characterization of an immunosuppressive factor derived from colon cancer cells

1 reference

12 December 2020

Inhibition of interleukin 2 production by factors released from tumor cells.

1 reference

12 December 2020

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

1 reference

12 December 2020

Inhibition of cytokine production by a tumor cell product.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00205800

1 reference

Dimensions Publication ID

26 November 2017

1013291163

0 references

1 reference